Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Imagine Pharma has developed a novel polypeptide, IMG‑1, with three distinct platforms targeting oral delivery, therapeutics, and regenerative medicine. The company has completed over 40 clinical human islet cell isolation procedures for leading healthcare institutions and recently launched a dietary supplement while advancing pill-based therapies for metabolic diseases such as diabetes. It also operates an approved Islet Isolation Center for the National Institute of Diabetes and Digestive and Kidney Diseases Integrated Islet Distribution Program.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Imagimed.